Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
High-risk early HR-positive breast cancer
What changed

High-risk early HR-positive breast cancer

What changed: High-risk early HR-positive breast cancer

Cancer page →

Every dated change on the records linked to High-risk early HR-positive breast cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Trial result10Milestone10This record1On Edge

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordHigh-risk early HR-positive breast cancer
Facts on this page last checked
When this page itself was last checked or edited.

2025 · 2

2025Trial resultlidERA
lidERA reported
iDFS ~30% relative reduction (HR ~0.
2025MilestonelidERA
lidERA: adjuvant giredestrant improves invasive disease-free survival
A milestone in how this cancer is treated.

2023 · 2

2023Trial resultNATALEE
NATALEE reported
iDFS HR 0.
2023MilestoneNATALEE
NATALEE: adjuvant ribociclib in stage II to III disease
A milestone in how this cancer is treated.

2021 · 2

2021Trial resultOlympiA
OlympiA reported
iDFS HR 0.
2021Trial resultPENELOPE-B
PENELOPE-B reported
One year of palbociclib added to endocrine therapy did not improve invasive disease-free survival.

2020 · 4

2020Trial resultmonarchE
monarchE reported
iDFS HR 0.
2020Trial resultPALLAS & PENELOPE-B
PALLAS & PENELOPE-B reported
PALLAS iDFS HR 0.
2020Trial resultRxPONDER (SWOG S1007)
RxPONDER (SWOG S1007) reported
No chemo benefit postmenopausal; iDFS HR 0.
2020MilestonemonarchE
monarchE: adjuvant abemaciclib; RxPONDER in node-positive disease
A milestone in how this cancer is treated.

2018 · 2

2018Trial resultTAILORx
TAILORx reported
9-year iDFS 83.
2018MilestoneTAILORx
TAILORx: no chemotherapy benefit for intermediate recurrence scores
A milestone in how this cancer is treated.

2016 · 2

2016Trial resultMINDACT
MINDACT reported
5-year distant metastasis-free survival 94.
2016MilestoneMINDACT
MINDACT: genomic low-risk women can skip chemotherapy
A milestone in how this cancer is treated.

2014 · 2

2014Trial resultSOFT & TEXT
SOFT & TEXT reported
Exemestane + OFS: DFS and DRFI improved; no OS difference at 12 years.
2014MilestoneSOFT & TEXT
SOFT and TEXT: ovarian suppression with exemestane in premenopausal women
A milestone in how this cancer is treated.

2013 · 1

2013MilestoneTamoxifen
ATLAS: ten years of tamoxifen beats five
A milestone in how this cancer is treated.

2004 · 1

2004MilestoneLetrozole (and other aromatase inhibitors)
MA.17: letrozole after five years of tamoxifen reduces late recurrence
A milestone in how this cancer is treated.

1998 · 1

1998MilestoneTamoxifen
EBCTCG overview: five years of tamoxifen cuts recurrence and death
A milestone in how this cancer is treated.

1977 · 1

1977MilestoneTamoxifen
Tamoxifen approved
A milestone in how this cancer is treated.